MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”
Key Highlights & Upcoming Milestones
Financial Results for the Quarter Ended September 30, 2026
Research and Development (R&D) expense was $2.2 million for the quarter ended September 30, 2026, compared to $3.0 million for the three months ended September 30, 2025. The decrease was primarily driven by a $1.2 million decrease in developments costs, which was partially offset by an increase in non-cash stock-based compensation of $0.5 million.
General and Administrative (G&A) expense was $6.6 million for the quarter ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily driven by a $0.6 million increase in non-cash stock-based compensation as well as an increase of $0.2 million in other labor costs. There was also an increase of $1.4 million related to commercial launch preparation.
Other income (expense) was $1.8 million for the quarter ended September 30, 2026, compared to $1.3 million income for the three months ended September 30, 2025, attributed primarily to the change in fair value of the Company’s warrant liability.
Net loss attributable to common stockholders, basic and diluted, for the quarter ended September 30, 2026, was $(7.0) million, or $(0.25) per share of common stock, compared to $(6.0) million, or $(0.33) per share of common stock, for the three months ended September 30, 2025. The increased net loss for the quarter ended September 30, 2026, was attributed primarily to an increase in commercial launch expenses.
Cash, cash equivalents and marketable securities were approximately $59 million as of September 30, 2026, with expected runway beyond 2027, including anticipated increased expenses related to the launch of OLC should it receive approval.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Unicycive Therapeutics
media@unicycive.com
SOURCE: Unicycive Therapeutics, Inc.
| Unicycive Therapeutics, Inc. | ||||||||
| Balance Sheets | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| As of | As of | |||||||
| December 31, | September 30, | |||||||
| 2025 | 2026 | |||||||
| Assets | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash | $ | 29,198 | $ | 41,966 | ||||
| Prepaid expenses and other current assets | 7,692 | 10,187 | ||||||
| Marketable securities | 12,071 | 17,006 | ||||||
| Total current assets | 48,961 | 69,159 | ||||||
| Right of use asset, net | 108 | 519 | ||||||
| Property and equipment, net | 66 | 255 | ||||||
| Total assets | $ | 49,135 | $ | 69,933 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 383 | $ | 1,030 | ||||
| Accrued liabilities | 1,523 | 3,380 | ||||||
| Warrant liability | 16,915 | 12,377 | ||||||
| Operating lease liability - current | 117 | 522 | ||||||
| Total current liabilities | 18,938 | 17,309 | ||||||
| Operating lease liability - long term | - | - | ||||||
| Total liabilities | 18,938 | 17,309 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Series A-2 Prime preferred stock, $0.001 par value per share - 21,388.01 Series A-2 Prime shares authorized at December 31, 2025, and September 30, 2026; 2,265 and zero Series A-2 Prime shares issued and outstanding at December 31, 2025, and September 30, 2026, respectively | - | - | ||||||
| Series B-2 preferred stock, $0.001 par value per share - 50,000 Series B-2 shares authorized at December 31, 2025, and September 30, 2026; zero Series B-2 shares issued and outstanding at December 31, 2025, and September 30, 2026 | - | - | ||||||
| Preferred stock, $0.001 par value per share- 10,000,000 shares authorized at December 31, 2025, and June 30, 2026; zero shares issued and outstanding at December 31, 2025, and June 30, 2026 | - | - | ||||||
| Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2025, and September 30, 2026; 22,114,245 and 29,110,352 shares issued and outstanding at December 31, 2025, and September 30, 2026, respectively | 22 | 29 | ||||||
| Accumulated other comprehensive loss | (1 | ) | (26 | ) | ||||
| Additional paid-in capital | 158,001 | 201,988 | ||||||
| Accumulated deficit | (127,825 | ) | (149,367 | ) | ||||
| Total stockholders’ equity | 30,197 | 52,624 | ||||||
| Total liabilities and stockholders’ equity | $ | 49,135 | $ | 69,933 | ||||
| Unicycive Therapeutics, Inc. | ||||||||
| Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2025 | 2026 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 2,964 | $ | 2,246 | ||||
| General and administrative | 4,378 | 6,595 | ||||||
| Total operating expenses | 7,342 | 8,841 | ||||||
| Loss from operations | (7,342 | ) | (8,841 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 279 | 503 | ||||||
| Interest expense | (15 | ) | - | |||||
| Change in fair value of warrant liability | 1,067 | 1,341 | ||||||
| Total other income (expenses) | 1,331 | 1,844 | ||||||
| Net loss | (6,011 | ) | (6,997 | ) | ||||
| Other comprehensive loss: | ||||||||
| Unrealized loss on marketable securities, net | - | (3 | ) | |||||
| Net comprehensive loss | $ | (6,011 | ) | $ | (7,000 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.33 | ) | $ | (0.25 | ) | ||
| Weighted-average shares outstanding used in computing net loss per share | 18,065,389 | 28,270,842 | ||||||

| 12 hours | |
| Nov-16 | |
| Nov-04 | |
| Oct-21 | |
| Oct-21 | |
| Oct-21 | |
| Oct-19 | |
| Oct-01 | |
| Sep-29 | |
| Sep-29 | |
| Sep-15 | |
| Sep-11 | |
| Sep-07 | |
| Sep-01 | |
| Aug-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite